PENZBERG, Germany--(BUSINESS WIRE)--The new xCELLigence System RTCA HT Instrument from Roche Diagnostics (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) rounds out the company’s portfolio in real-time cell analysis with a high-throughput product. The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications. The system allows researchers to run 1 to 4 plates independently on up to four RTCA HT stations, thus reading 4 x384 well plates in parallel. Integration with automated plate and liquid handling systems is also an option. The instrument was launched worldwide and will be available in all markets during the next months.
